2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro Apr 15, 2018
2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples Apr 15, 2018
2017 ASH Poster - CG’806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition as a Single Agent and in Combination with a BET Bromodomain Inhibitor and a Bcl2 Inhibitor Against AML and CLL Patient Samples Dec 11, 2017
2017 ASH Poster - CG’806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutational Status Dec 11, 2017
2017 ASH Poster - The Pan-FLT3/BTK Multi-Kinase Inhibitor CG’806 Induces AML Killing in FLT-Mutant and Wild Type Cells, and Exerts Synergistic Pro-Apoptotic Effects with Concomitant Targeting of Anti-Apoptotic Bcl-2 and/or Mcl-1 Dec 10, 2017
2017 AACR Hematologic Malignancies Conference - CG’806, a First‐in‐Class FLT3/BTK Inhibitor, Exerts Superior Potency Against AML Cells Harboring FLT3‐ITD, TKD, and Gatekeeper Mutant or Wild‐Type FLT3 May 7, 2017
2017 AACR Hematologic Malignancies Conference - CG’806, a First-in-Class FLT3/BTK Inhibitor, Exhibits Potent Activity Against AML May 7, 2017
2016 ASH Poster - Inhibition of c-Myc by APTO-253 as an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia Dec 3, 2016
